Soper J T, Segreti E M, Novotny D B, Mutch D, Creasman W T, McCarty K S
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710.
Gynecol Oncol. 1990 Mar;36(3):363-8. doi: 10.1016/0090-8258(90)90143-9.
Estrogen (ER) and progesterone (PgR) receptor values in 105 endometrial carcinomas were compared using immunocytochemical and standard biochemical techniques. Peroxidase-antiperoxidase staining for location of anti-ER (H222) and anti-PgR (JZB39) primary antibodies was used to generate a semiquantitative (HSCORE) assessment of receptor content in tissue components and the total specimen. Both total HSCORE and cancer component HSCORE correlated with log biochemical assay values for ER and PgR. Biochemical assay values, total HSCORE, and cancer component HSCORES all demonstrated internal correlations between ER and PgR levels. Correlation was somewhat closer for cancer component HSCORE values of ER and PgR than the values for total tissue HSCORE. When receptor content was analyzed by histologic grade, all three estimates of receptor status demonstrated a decreasing proportion of ER and PgR positive lesions with decreasing histologic differentiation; however, the proportion of receptor negative lesions in grade 3 lesions was much higher when using total HSCORE or cancer component HSCORE than when using biochemical assay values (P less than 0.005. Immunocytochemical techniques for localization of ER and PgR in endometrial carcinoma specimens may allow a more focused evaluation of the receptor content in the malignant elements than standard biochemical techniques.
采用免疫细胞化学和标准生化技术,对105例子宫内膜癌中的雌激素(ER)和孕激素(PgR)受体值进行了比较。使用过氧化物酶-抗过氧化物酶染色法来定位抗ER(H222)和抗PgR(JZB39)一抗,以对组织成分和整个标本中的受体含量进行半定量(HSCORE)评估。总HSCORE和癌组织成分HSCORE均与ER和PgR的对数生化检测值相关。生化检测值、总HSCORE和癌组织成分HSCORE均显示出ER和PgR水平之间的内在相关性。ER和PgR的癌组织成分HSCORE值之间的相关性比整个组织HSCORE值之间的相关性更为紧密。当按组织学分级分析受体含量时,随着组织学分化程度降低,受体状态的所有三种评估均显示ER和PgR阳性病变的比例下降;然而,在3级病变中,使用总HSCORE或癌组织成分HSCORE时受体阴性病变的比例远高于使用生化检测值时(P小于0.005)。与标准生化技术相比,免疫细胞化学技术用于子宫内膜癌标本中ER和PgR的定位,可能会对恶性成分中的受体含量进行更有针对性的评估。